The transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases ...
ORIGIN 3 randomized 431 biopsy‑confirmed IgAN patients 1:1; atacicept 150 mg weekly SC produced the largest placebo‑adjusted UPCR reduction reported at week 36. Accelerated approval hinged on ...
The Food and Drug Administration has cleared a new treatment from Vera Therapeutics in the latest step forward for an emerging class of medications that have shown the ability to combat a rare and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results